Sign In
Buy BNTX
$89.59
+1.14 (+1.29%)
At Close: Jun 04, 2026
BioNTech on the verge of UK trials of cancer vaccine - here's our two-minute guide
11:31am, Monday, 20'th Feb 2023
BioNTech plans to begin clinical trials for its cancer vaccines in the UK this year, according to the company's CEO, Ugur Sahin quoted in the German press. The drug developer, which is best known for
The 3 Most Undervalued Growth Stocks for Your February Buy List
06:15am, Monday, 06'th Feb 2023
Undervalued growth stocks are often overlooked by investors, they can offer significant potential for capital appreciation. One way to identify undervalued growth stocks is to look for companies with
Better Buy: Novavax or BioNTech Stock?
08:00am, Saturday, 04'th Feb 2023
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
02:19pm, Thursday, 02'nd Feb 2023
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg
Mergers and Acquisitions in 2023 Off To A Strong Start
08:17am, Friday, 27'th Jan 2023
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $
Ranking The 10 Largest Biotechs By Pipeline
12:34pm, Wednesday, 11'th Jan 2023
The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment
BioNTech SE (BNTX) JP Morgan Annual Healthcare Conference - (Transcript)
09:32am, Wednesday, 11'th Jan 2023
BioNTech SE (NASDAQ:BNTX ) JP Morgan Annual Healthcare Conference January 10, 2023 12:45 PM ET Company Participants Ugur Sahin - Chief Executive Officer & Co-Founder Ryan Richardson - Chief Strategy O
BioNTech makes £562 million foray into AI as it swoops for UK start-up
03:28am, Wednesday, 11'th Jan 2023
BioNTech, the biotech company known for its role in developing a COVID-19 vaccine, has agreed to acquire UK-based artificial intelligence (AI) start-up InstaDeep for £562 million. The deal, the Germ
BioNTech acquires Tunisian-born and U.K-based AI startup InstaDeep for £562M
12:09pm, Tuesday, 10'th Jan 2023
German-based biotech company BioNTech SE is set to acquire InstaDeep, a Tunis-born and U.K.-based artificial intelligence (AI) startup InstaDeep for up to £562 million (~$680 million) in its largest
BioNTech to acquire AI company
07:53am, Tuesday, 10'th Jan 2023
BioNTech SE BNTX, -0.89% said Tuesday that it plans to acquire InstaDeep Ltd., a privately held provider of artificial intelligence and machine learning, for £362 million ($439.2 million), with miles
BioNTech cancer treatments deal is a coup for the government and a challenge for the NHS
12:29pm, Friday, 06'th Jan 2023
BioNTech has signed a deal with the UK government to enrol up to 10,000 patients in clinical trials by the end of 2030 for personalised cancer therapies.
Cancer Vaccine Trials—Using Same mRNA Tech Behind Covid Shots—Could Launch In U.K. This September
08:40am, Friday, 06'th Jan 2023
BioNTech, which worked with Pfizer to build an mRNA Covid vaccine, has partnered with the U.K. to turn the technology towards cancer and plans to treat 10,000 people by 2030.
BioNTech says it will start cancer vaccine trials in the UK from September
08:35am, Friday, 06'th Jan 2023
The company aims to test 10,000 personalized mRNA therapies, including cancer vaccines, between September 2023 to the end of the decade.
UK government inks landmark deal with BioNTech to create cancer vaccine
03:01am, Friday, 06'th Jan 2023
The UK government is partnering with BioNTech to enrol up to 10,000 patients in clinical trials for advanced cancer treatments, according to the Financial Times, BioNTech, which developed the best-sel
BioNTech: Covid Market Expansion Plus CAR-T Therapy Improvements
05:05pm, Tuesday, 03'rd Jan 2023
For the 3 months ending September 30, 2022, BioNTech SE produced $3.65 billion in revenues for its Covid-19 vaccine Comirnaty. BioNTech has potential for Covid-19 market expansion with an enhanced spi
